Mortality Rates of Myeloma Patients in the COVID Era

Patients with cancer frequently exhibit poorer post-COVID-19 infection outcomes, therefore the management of patients with hematological malignancies remains of high importance. Several strategies have been employed to reduce the risk of infection, whilst still providing appropriate therapies for high-risk patients.

In this podcast, Paul Richardson, of the Dana-Farber Cancer Institute, Boston, MA, chairs a thoughtful discussion with María-Victoria Mateos of the University Hospital of Salamanca, Salamanca, Spain, Evangelos Terpos of the University of Athens, Athens, Greece, and Ajai Chari of Mount Sinai, New York, NY, on the treatment of multiple myeloma in the face of the COVID-19 pandemic. The speakers discuss evolving strategies to reduce risk of COVID-19 infection in myeloma patients, perspectives from Spain, New York, and Greece, recommendations from the International Myeloma Society (IMS), as well as the key updates following the virtual ASCO and EHA meetings.

The post The Myeloma Sessions: Evolving management of myeloma & COVID-19 appeared first on VJHemOnc.